Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722173 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket



NeoCardiogenesis- Celebrating The Birth Of Regenerative Cardiology
MRI Limited (Meta Reports), Nov 2008, Pages: 312

  Description  

  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

AB INITIO

Chapter 1: EXECUTIVE SUMMARY
I.A Reasons For Conducting The Study
I.B Study Goals & Objectives
I.C Target Audience
I.D Sponsorships
I.E Scope & Format
I.F Methodology
I.G Information Sources
I.H Related Projects By This Publisher
I.I Conclusion

Chapter 2: The Industry
II.A CAD - The Problem
II.B CAD - The Current Solutions
II.C CAD - More Problems – The Triple Paradox of Revascularization
II.D CAD - The Unmet Need
II.E CAD - NeoCardiogenesis - The Next Frontier

Chapter 3: The Folkman Hypothesis
III.A History And Evolution Of The Angiogenesis Phenomenon
III.B Angiogenesis and Diseases
III.C The Angiogenesis Modulators
III.D The Initial Successes
III.E Indications Beyond Cancers- Therapeutic Angiogenesis
III.F Indications Beyond Cancers- Diagnostics

Chapter 4: FOLKMAN LEGACY – Therapeutic Angiogenesis
IV.A Myocardial Reperfusion
IV.B Myocardial Regeneration
IV.C Plaque Regression
IV.D Tackling Obesity – Another Folkman Hypothesis Coming Of Age
IV.E Angiogenic Switch – Folkman Legacy Continues

Chapter 5: CHANGE OF HEART – Neocardiogenesis: The New Paradigm
V.A All Roads Lead To Bone Marrow
V.B Residential CSC Pool
V.C Cardiac Regeneration – Blend of Myogenesis & Angiogenesis
V.D Broken Hearts May Mend After All?

Chapter 6: STEM CELLS – The Regeneration Revolution
VI.A Stemness
VI.B Stem Cell Regulation
VI.C Stem Cell Niches
VI.D Regenerating Heart

Chapter 7: CARDIO CANONS – The Master Regulators
VII.A The HIF Pathway
VII.B The PGC-8 Pathway
VII.C Notch, Wnt/ß-catenin, Hedgehog & Other Pathways
VII.D The Neocardiogenesis Cascade
VII.E The Angiogenic Switch

Chapter 8: CLINICAL TRIALS - The First Wave
VIII.A Of Bulls & Bears
VIII.B Gene Therapy Trials
VIII.C Protein Therapy Trials
VIII.D Cell Therapy Trials

Chapter 9: SECOND WAVE – The Gold Rush
IX.A State Of The Cell Therapy Trials
IX.B The Bulls Are Back?
IX.C Select Ongoing Trials
IX.D Looking Forward

Chapter 10: THE PLACEBO EFFECT – The Specter Still Haunting?
X.A Is Angiogenesis Therapy Dead?
X.B Myogenesis – Placebo Effect Still Riding High?
X.C The Placebo
X.D The Hrobjartsson Test
X.E Biggest Placebo Effect Of All Time That Sired A Nobel Prize & A Blockbuster Drug
X.F Searching For The Real Culprit
X.G Is Angiogenesis Therapy Dead?

Chapter11: TRANSLATIONAL PARADOX – Neocardiogenesis: A Whole Different Ballgame
XI.A Mother Nature’s Secret
XI.B Hypoxia Vs Normoxia – The Homeostatic Balance
XI.C Hypoxia – Lost In Translation?
XI.D Normoxia - Impact On Neocardiogenesis Modulators
XI.E Translational Paradox – Secrets Revealed

Chapter 12: CATCH 22- Obsolescence Of Convention
XII.A Simpson’s Paradox
XII.B The Intrinsic Confounders
XII.C The Extrinsic Confounders
XII.D The Clinical Protocols
XII.E The Treadmill Fallacies – Of Apples & Oranges
XII.F Myocardial Preconditioning
XII.G Obsolescence Of Convention
XII.H Catching Up With The Triple Cripple

Chapter 13: WAY OUT- Ridding The Triple Cripple
XIII.A Resolving Simpson’s Paradox
XIII.B Measuring The Intrinsic Confounders
XIII.C Recruiting the Missing Switch
XIII.D Triphasic Regenerative Cardiology (TRC) Treatment Regimen
XIII.E Road Ahead

Chapter 14: THE CONCLUSION
XIV.A Goals Achieved
XIV.B Beyond Goals – Serendipity Finds New Abode
XIV.C Neocardiogenesis – A Second Coming

Chapter 15: AFTERWORD

APPENDIX: Neocardiogenesis- The Players

A. Aastrom Biosciences, Inc., Abbott Laboratories, Advanced Cell Technologies, Inc, Aldagen, Inc., Amorcyte, Inc AnGes MG, Inc, AngioB Limited, Angioblast Systems, Inc., Angiotech Pharmaceuticals, Inc., Ark Pharmaceuticals, Arteriocyte, Inc., Athersys, Inc., Axiogenesis, AG, Axordia, Ltd

B. Baxter Healthcare, BeFutur Biotechnologies SA, BioCardia, Inc., Bioheart, Inc., Boston Scientific Corporation.

C. California Stem Cell, Inc, Cardio, Inc., Cardio3 Biosciences, CardioGenesis, Corp., Cardion AG, CardioVascular BioTherapeutics, Inc., Cardium Therapeutics, Inc., Cellartis AB, Chiron / Novartis AG, Corautus/ Via Pharmaceuticals, Cordis Corp, Curis, Inc., Cytori Therapeutics, Inc.

E. EndGenitor Technologies, Inc., Endothelix, Inc., Endovasc/ Angiogenix/ Athenagen/ CoMentis, ES Cell International Pte Ltd, Euriogentec SA, EVGN European Vascular Genomics Network

G. Gamida Cell Ltd., Gencell/ Centelion/ Sanofi Aventis, Genentech, Inc., GenVec, Inc., Genzyme Corp, Geron Corporation, Geymonat S.p.A.

H. HealtheUniverse, Heart BioSystems GmbH, Hydra Biosciences, Inc., Hypertension Diagnostics, Inc.

I. Itamar Medical Ltd

L. Lazaron Biotechnologies (SA) Ltd, Lombard Medical Technologies PLC

M. Medcel Bioscience Ltd/ NovaThera Ltd, Medistem Laboratories, Inc, Medtronic, Inc., MG Biotherapeutics, Meridien Co. Ltd, Mesoblast Ltd., Millipore, Corp., Miltenyi Biotec GmbH, Mytogen, Inc

N. NanoCor Therapeutics Inc, Neuronyx, Inc., Novus Sanguis

O. Opexa Therapeutics, Osiris Therapeutics, Inc.

P. PLC Systems, Inc, PrimeGen Biotech LLC

R. RegeneRx Biopharmaceuticals, Inc., Regenetech, Inc, Reliance Life Sciences, Royan Institute

S. Saneron CCEL Therapeutics, Inc, Scios, Inc., Stem Cell Therapy International, Corp., Stemedica Cell Technologies, Inc., Sunway Biotech Co. Ltd., SynovisLife Technologies, Inc.

T. t2cure GmbH, TCA Cellular Therapy, LLC, TheraVitae Israel Ltd, Theregen, Inc., ThromboGenics NV

V. Valentis Inc. / Urigen / Inovio, Vascular Biogenics Ltd, Vasoplus Consortium, ViaCell, Inc., Vical, Inc., ViroMed Co. Ltd, VistaGen Therapeutics, Inc.

X. Xcell Center

Product samples

Samples for this product is available. Please Login/Register to download these samples.

Customers who bought this item also bought

Stem Cell Research in Cardiology

Cell Therapy - Technologies, Markets and Companies

Cell Therapy Clinical Trial Analysis

Heart Repair: A Placebo Fix? Or A Nocebo Mix?

Angiogenesis Modulators

Cell Therapy Markets

Stem Cell Research 2008

Interventional Cardiology Clinical Trial Analysis

Stem Cells in Regenerative Medicine 2008 Market Report

Angiogenesis Modulators: Strategies for Drug Discovery

Regenerative Medicine - Global Strategic Business Report

Current Clinical Applications and Trials of Stem Cell - Based Therapies



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds